

6. Literaturverzeichnis

1. Kolb, H., U. Worz-Pagenstert, R. Kleemann, H. Rothe, P. Rowsell, S. Rastegar, and F.W. Scott, *Insulin therapy of prediabetes suppresses TH1 associated gene expression in BB rat pancreas*. *Autoimmunity*, 1997. 26(1): p. 1-6.
2. Gerich, J.E., *The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity*. *Endocr Rev*, 1998. 19(4): p. 491-503.
3. King, H., R.E. Aubert, and W.H. Herman, *Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections*. *Diabetes Care*, 1998. 21(9): p. 1414-31.
4. Hauner, H., L. von Ferber, and I. Koster, *[Estimation of the incidence of diabetes in the Federal Republic of Germany based on insurance data. A secondary data analysis of a representative random sample of locally insured persons in the city of Dortmund]*. *Dtsch Med Wochenschr*, 1992. 117(17): p. 645-50.
5. Hauner, H., *[Occurrence of diabetes mellitus in Germany]*. *Dtsch Med Wochenschr*, 1998. 123(24): p. 777-82.
6. McMurray, J.J. and M.A. Pfeffer, *Heart failure*. *Lancet*, 2005. 365(9474): p. 1877-89.
7. Stewart, S., K. MacIntyre, S. Capewell, and J.J. McMurray, *Heart failure and the aging population: an increasing burden in the 21st century?* *Heart*, 2003. 89(1): p. 49-53.

8. Kupari, M., M. Lindroos, A.M. Iivanainen, J. Heikkilä, and R. Tilvis, *Congestive heart failure in old age: prevalence, mechanisms and 4-year prognosis in the Helsinki Ageing Study*. *J Intern Med*, 1997. 241(5): p. 387-94.
9. Grundy, S.M., I.J. Benjamin, G.L. Burke, A. Chait, R.H. Eckel, B.V. Howard, W. Mitch, S.C. Smith, Jr., and J.R. Sowers, *Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association*. *Circulation*, 1999. 100(10): p. 1134-46.
10. Borch-Johnsen, K., H. Nissen, E. Henriksen, S. Kreiner, N. Salling, T. Deckert, and J. Nerup, *The natural history of insulin-dependent diabetes mellitus in Denmark: 1. Long-term survival with and without late diabetic complications*. *Diabet Med*, 1987. 4(3): p. 201-10.
11. Krolewski, A.S., J.H. Warram, L.I. Rand, and C.R. Kahn, *Epidemiologic approach to the etiology of type I diabetes mellitus and its complications*. *N Engl J Med*, 1987. 317(22): p. 1390-8.
12. Krolewski, A.S., E.J. Kosinski, J.H. Warram, O.S. Leland, E.J. Busick, A.C. Asmal, L.I. Rand, A.R. Christlieb, R.F. Bradley, and C.R. Kahn, *Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus*. *Am J Cardiol*, 1987. 59(8): p. 750-5.
13. Zannad, F., S. Briançon, Y. Juillière, P.M. Mertes, J.P. Villemot, F. Alla, and J.M. Virion, *Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study*. *Epidemiologie de l'Insuffisance Cardiaque Avancée en Lorraine*. *J Am Coll Cardiol*, 1999. 33(3): p. 734-42.

14. Cohn, J.N., G. Johnson, S. Ziesche, F. Cobb, G. Francis, F. Tristani, R. Smith, W.B. Dunkman, H. Loeb, M. Wong, and et al., *A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure*. N Engl J Med, 1991. 325(5): p. 303-10.
15. Shindler, D.M., J.B. Kostis, S. Yusuf, M.A. Quinones, B. Pitt, D. Stewart, T. Pinkett, J.K. Ghali, and A.C. Wilson, *Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry*. Am J Cardiol, 1996. 77(11): p. 1017-20.
16. Ryden, L., P.W. Armstrong, J.G. Cleland, J.D. Horowitz, B.M. Massie, M. Packer, and P.A. Poole-Wilson, *Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial*. Eur Heart J, 2000. 21(23): p. 1967-78.
17. Karlefors, T., *Haemodynamic studies in male diabetics*. Acta Med Scand Suppl, 1966. 449: p. 45-80.
18. Poornima, I.G., P. Parikh, and R.P. Shannon, *Diabetic cardiomyopathy: the search for a unifying hypothesis*. Circ Res, 2006. 98(5): p. 596-605.
19. Messina, E. and A. Giacomello, *Diabetic cardiomyopathy: a "cardiac stem cell disease" involving p66Shc, an attractive novel molecular target for heart failure therapy*. Circ Res, 2006. 99(1): p. 1-2.
20. Spallone, V., L. Bernardi, L. Ricordi, P. Solda, M.R. Maiello, A. Calciati, S. Gambardella, P. Fratino, and G. Menzinger, *Relationship between the*

- circadian rhythms of blood pressure and sympathovagal balance in diabetic autonomic neuropathy.* Diabetes, 1993. 42(12): p. 1745-52.
21. Kass, D.A., J.G. Bronzwaer, and W.J. Paulus, *What mechanisms underlie diastolic dysfunction in heart failure?* Circ Res, 2004. 94(12): p. 1533-42.
 22. Baan, J., E.T. van der Velde, H.G. de Bruin, G.J. Smeenk, J. Koops, A.D. van Dijk, D. Temmerman, J. Senden, and B. Buis, *Continuous measurement of left ventricular volume in animals and humans by conductance catheter.* Circulation, 1984. 70(5): p. 812-23.
 23. Georgakopoulos, D. and D. Kass, *Minimal force-frequency modulation of inotropy and relaxation of in situ murine heart.* J Physiol, 2001. 534(Pt. 2): p. 535-45.
 24. Feldman, M.D., Y. Mao, J.W. Valvano, J.A. Pearce, and G.L. Freeman, *Development of a multifrequency conductance catheter-based system to determine LV function in mice.* Am J Physiol Heart Circ Physiol, 2000. 279(3): p. H1411-20.
 25. Herr, R.R., T.E. Eble, M.E. Bergy, and H.K. Jahnke, *Isolation and characterization of streptozotocin.* Antibiot Annu, 1959. 7: p. 236-40.
 26. Arison, R.N. and E.L. Feudale, *Induction of renal tumour by streptozotocin in rats.* Nature, 1967. 214(94): p. 1254-5.
 27. Rakieten, N., M.L. Rakieten, and M.V. Nadkarni, *Studies on the diabetogenic action of streptozotocin (NSC-37917).* Cancer Chemother Rep, 1963. 29: p. 91-8.

28. Dorenkamp, M., A. Riad, S. Stiehl, F. Spillmann, D. Westermann, J. Du, M. Pauschinger, M. Noutsias, V. Adams, H.P. Schultheiss, and C. Tschope, *Protection against oxidative stress in diabetic rats: role of angiotensin AT(1) receptor and beta 1-adrenoceptor antagonism*. Eur J Pharmacol, 2005. 520(1-3): p. 179-87.
29. Tschope, C., D. Westermann, P. Steendijk, M. Noutsias, S. Rutschow, A. Weitz, P.L. Schwimmbeck, H.P. Schultheiss, and M. Pauschinger, *Hemodynamic characterization of left ventricular function in experimental coxsackieviral myocarditis: effects of carvedilol and metoprolol*. Eur J Pharmacol, 2004. 491(2-3): p. 173-9.
30. Steendijk, P., E. Staal, J.W. Jukema, and J. Baan, *Hypertonic saline method accurately determines parallel conductance for dual-field conductance catheter*. Am J Physiol Heart Circ Physiol, 2001. 281(2): p. H755-63.
31. Burkhoff, D., I. Mirsky, and H. Suga, *Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers*. Am J Physiol Heart Circ Physiol, 2005. 289(2): p. H501-12.
32. Sonnenblick, E.H., W.H. Frishman, and T.H. LeJemtel, *Dobutamine: a new synthetic cardioactive sympathetic amine*. N Engl J Med, 1979. 300(1): p. 17-22.
33. Koch, M., M. Wendorf, A. Dendorfer, S. Wolfrum, K. Schulze, F. Spillmann, H.P. Schultheiss, and C. Tschope, *Cardiac kinin level in experimental diabetes*

- mellitus: role of kininases*. Am J Physiol Heart Circ Physiol, 2003. 285(1): p. H418-23.
34. Tschope, C., F. Spillmann, U. Rehfeld, M. Koch, D. Westermann, C. Altmann, A. Dendorfer, T. Walther, M. Bader, M. Paul, H.P. Schultheiss, and R. Vetter, *Improvement of defective sarcoplasmic reticulum Ca²⁺ transport in diabetic heart of transgenic rats expressing the human kallikrein-1 gene*. Faseb J, 2004. 18(15): p. 1967-9.
35. Bombardini, T., *Myocardial contractility in the echo lab: molecular, cellular and pathophysiological basis*. Cardiovasc Ultrasound, 2005. 3(1): p. 27.
36. Riad, A., D. Unger, J. Du, D. Westermann, Z. Mohr, M. Sobirey, M. Dorenkamp, H.P. Schultheiss, and C. Tschope, *Chronic inhibition of p38MAPK improves cardiac and endothelial function in experimental diabetes mellitus*. Eur J Pharmacol, 2007. 554(1): p. 40-5.
37. Al-Shafei, A.I., R.G. Wise, G.A. Gresham, T.A. Carpenter, L.D. Hall, and C.L. Huang, *Magnetic resonance imaging analysis of cardiac cycle events in diabetic rats: the effect of angiotensin-converting enzyme inhibition*. J Physiol, 2002. 538(Pt 2): p. 555-72.
38. Kandolf, R., K. Klingel, R. Zell, H.C. Selinka, U. Raab, W. Schneider-Brachert, and B. Bultmann, *Molecular pathogenesis of enterovirus-induced myocarditis: virus persistence and chronic inflammation*. Intervirology, 1993. 35(1-4): p. 140-51.

39. Beck, M.A., D. Williams-Toone, and O.A. Levander, *Coxsackievirus B3-resistant mice become susceptible in Se/vitamin E deficiency*. Free Radic Biol Med, 2003. 34(10): p. 1263-70.
40. Riad, A., J. Du, S. Stiehl, D. Westermann, Z. Mohr, M. Sobirey, W. Doehner, V. Adams, M. Pauschinger, H.P. Schultheiss, and C. Tschope, *Low-dose treatment with atorvastatin leads to anti-oxidative and anti-inflammatory effects in diabetes mellitus*. Eur J Pharmacol, 2007. 569(3): p. 204-11.
41. Tschope, C., T. Walther, J. Koniger, F. Spillmann, D. Westermann, F. Escher, M. Pauschinger, J.B. Pesquero, M. Bader, H.P. Schultheiss, and M. Noutsias, *Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene*. Faseb J, 2004. 18(7): p. 828-35.
42. Tschope, C., T. Walther, F. Escher, F. Spillmann, J. Du, C. Altmann, I. Schimke, M. Bader, C.F. Sanchez-Ferrer, H.P. Schultheiss, and M. Noutsias, *Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction and oxidative stress in experimental diabetic cardiomyopathy*. Faseb J, 2005. 19(14): p. 2057-9.
43. Baan, J., E.T. van der Velde, and P. Steendijk, *Ventricular pressure-volume relations in vivo*. Eur Heart J, 1992. 13 Suppl E: p. 2-6.
44. Zile, M.R., C.F. Baicu, and W.H. Gaasch, *Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle*. N Engl J Med, 2004. 350(19): p. 1953-9.

45. Yamamoto, K., T. Masuyama, Y. Sakata, N. Nishikawa, T. Mano, J. Yoshida, T. Miwa, M. Sugawara, Y. Yamaguchi, T. Ookawara, K. Suzuki, and M. Hori, *Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart*. Cardiovasc Res, 2002. 55(1): p. 76-82.
46. Cingolani, O.H., X.P. Yang, M.A. Cavasin, and O.A. Carretero, *Increased systolic performance with diastolic dysfunction in adult spontaneously hypertensive rats*. Hypertension, 2003. 41(2): p. 249-54.
47. Paulus, W.J., C. Tschope, J.E. Sanderson, C. Rusconi, F.A. Flachskampf, F.E. Rademakers, P. Marino, O.A. Smiseth, G. De Keulenaer, A.F. Leite-Moreira, A. Borbely, I. Edes, M.L. Handoko, S. Heymans, N. Pezzali, B. Pieske, K. Dickstein, A.G. Fraser, and D.L. Brutsaert, *How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology*. Eur Heart J, 2007. 28(20): p. 2539-50.
48. Altan, V.M., E. Arioglu, S. Guner, and A.T. Ozcelikay, *The influence of diabetes on cardiac beta-adrenoceptor subtypes*. Heart Fail Rev, 2007. 12(1): p. 58-65.
49. Westermann, D., B.C. Knollmann, P. Steendijk, S. Rutschow, A. Riad, M. Pauschinger, J.D. Potter, H.P. Schultheiss, and C. Tschope, *Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy*. Eur J Heart Fail, 2005.

50. Riad, A., J.L. Zhuo, H.P. Schultheiss, and C. Tschope, *The role of the renal kallikrein-kinin system in diabetic nephropathy*. *Curr Opin Nephrol Hypertens*, 2007. 16(1): p. 22-6.
51. Westermann, D., S. Rutschow, S. Jager, A. Linderer, S. Anker, A. Riad, T. Unger, H.P. Schultheiss, M. Pauschinger, and C. Tschope, *Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism*. *Diabetes*, 2007. 56(3): p. 641-6.
52. Westermann, D., S. Van Linthout, S. Dhayat, N. Dhayat, F. Escher, C. Bucker-Gartner, F. Spillmann, M. Noutsias, A. Riad, H.P. Schultheiss, and C. Tschope, *Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy*. *Diabetes*, 2007. 56(7): p. 1834-41.
53. Spector, K.S., *Diabetic cardiomyopathy*. *Clin Cardiol*, 1998. 21(12): p. 885-7.
54. Tschope, C. and H.P. Schultheiss, *[Diabetic cardiopathy: pathogenesis, diagnosis and therapy]*. *Internist (Berl)*, 2003. 44(7): p. 806-12, 814-8.
55. Haidara, M.A., H.Z. Yassin, M. Rateb, H. Ammar, and M.A. Zorkani, *Role of oxidative stress in development of cardiovascular complications in diabetes mellitus*. *Curr Vasc Pharmacol*, 2006. 4(3): p. 215-27.
56. Rodrigues, B., M.C. Cam, and J.H. McNeill, *Metabolic disturbances in diabetic cardiomyopathy*. *Mol Cell Biochem*, 1998. 180(1-2): p. 53-7.
57. Sonta, T., T. Inoguchi, H. Tsubouchi, N. Sekiguchi, K. Kobayashi, S. Matsumoto, H. Utsumi, and H. Nawata, *Evidence for contribution of vascular*

- NAD(P)H oxidase to increased oxidative stress in animal models of diabetes and obesity.* Free Radic Biol Med, 2004. 37(1): p. 115-23.
58. Vetter, R., U. Rehfeld, C. Reissfelder, W. Weiss, K.D. Wagner, J. Gunther, A. Hammes, C. Tschöpe, W. Dillmann, and M. Paul, *Transgenic overexpression of the sarcoplasmic reticulum Ca²⁺-ATPase improves reticular Ca²⁺ handling in normal and diabetic rat hearts.* Faseb J, 2002. 16(12): p. 1657-9.
59. Hayat, S.A., B. Patel, R.S. Khattar, and R.A. Malik, *Diabetic cardiomyopathy: mechanisms, diagnosis and treatment.* Clin Sci (Lond), 2004. 107(6): p. 539-57.
60. Bikkina, M., M.A. Alpert, R. Mukerji, M. Mulekar, B.Y. Cheng, and V. Mukerji, *Diminished short-term heart rate variability predicts inducible ventricular tachycardia.* Chest, 1998. 113(2): p. 312-6.
61. Kitamura, A., T. Hoshino, T. Kon, and R. Ogawa, *Patients with diabetic neuropathy are at risk of a greater intraoperative reduction in core temperature.* Anesthesiology, 2000. 92(5): p. 1311-8.
62. Stroud, J.D., C.F. Baicu, M.A. Barnes, F.G. Spinale, and M.R. Zile, *Viscoelastic properties of pressure overload hypertrophied myocardium: effect of serine protease treatment.* Am J Physiol Heart Circ Physiol, 2002. 282(6): p. H2324-35.
63. Giorgino, F., J.H. Chen, and R.J. Smith, *Changes in tyrosine phosphorylation of insulin receptors and a 170,000 molecular weight nonreceptor protein in vivo in skeletal muscle of streptozotocin-induced diabetic rats: effects of insulin and glucose.* Endocrinology, 1992. 130(3): p. 1433-44.

64. Van Voorhis, K., H.M. Said, N. Abumrad, and F.K. Ghishan, *Effect of chemically induced diabetes mellitus on glutamine transport in rat intestine*. Gastroenterology, 1990. 98(4): p. 862-6.
65. Riva, E., G. Andreoni, R. Bianchi, R. Latini, G. Luvara, G. Jeremic, C. Traquandi, and L. Tuccinardi, *Changes in diastolic function and collagen content in normotensive and hypertensive rats with long-term streptozotocin-induced diabetes*. Pharmacol Res, 1998. 37(3): p. 233-40.
66. Wang, J., Y. Song, L. Elsherif, Z. Song, G. Zhou, S.D. Prabhu, J.T. Saari, and L. Cai, *Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation*. Circulation, 2006. 113(4): p. 544-54.
67. Baan, J., T.T. Jong, P.L. Kerkhof, R.J. Moene, A.D. van Dijk, E.T. van der Velde, and J. Koops, *Continuous stroke volume and cardiac output from intraventricular dimensions obtained with impedance catheter*. Cardiovasc Res, 1981. 15(6): p. 328-34.
68. Feldman, M.D., J.M. Erikson, Y. Mao, C.E. Korcarz, R.M. Lang, and G.L. Freeman, *Validation of a mouse conductance system to determine LV volume: comparison to echocardiography and crystals*. Am J Physiol Heart Circ Physiol, 2000. 279(4): p. H1698-707.
69. Georgakopoulos, D., W.A. Mitzner, C.H. Chen, B.J. Byrne, H.D. Millar, J.M. Hare, and D.A. Kass, *In vivo murine left ventricular pressure-volume relations by miniaturized conductance micromanometry*. Am J Physiol, 1998. 274(4 Pt 2): p. H1416-22.

70. Kass, D.A., M. Midei, W. Graves, J.A. Brinker, and W.L. Maughan, *Use of a conductance (volume) catheter and transient inferior vena caval occlusion for rapid determination of pressure-volume relationships in man*. *Cathet Cardiovasc Diagn*, 1988. 15(3): p. 192-202.
71. Wallace, A., H.W. Lam, and D.T. Mangano, *Linearity, load dependence, hysteresis, and clinical associations of systolic and diastolic indices of left ventricular function in man*. *Multicenter Study of Perioperative Ischemia (McSPI) Research Group*. *J Card Surg*, 1995. 10(4 Suppl): p. 460-7.
72. Palmer, B.M., D. Georgakopoulos, P.M. Janssen, Y. Wang, N.R. Alpert, D.F. Belardi, S.P. Harris, R.L. Moss, P.G. Burgon, C.E. Seidman, J.G. Seidman, D.W. Maughan, and D.A. Kass, *Role of cardiac myosin binding protein C in sustaining left ventricular systolic stiffening*. *Circ Res*, 2004. 94(9): p. 1249-55.